Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 14 2024
0mins
Source: Newsfilter
Clinical Progress: Apollomics reported promising results for its vebreltinib program targeting non-CNS MET fusion tumors and NSCLC with MET amplification, achieving a 43% objective response rate in a recent Phase 2 trial. The company is focused on advancing this program towards regulatory submission.
Financial Overview: As of June 30, 2024, Apollomics had $25.9 million in cash, sufficient to fund operations into Q3 2025, despite a net loss of $35.2 million for the first half of 2024, which included a $10 million impairment loss related to uproleselan.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APLM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APLM
About APLM
Apollomics Inc. is a clinical-stage biopharmaceutical company focusing on discovering and developing oncology therapies to address unmet medical needs, especially for difficult-to-treat and treatment-resistant cancers. The product candidates in its pipeline are categorized into two groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumor inhibitors and immuno-oncology drugs. Its tumor inhibitor product candidates consist of three small-molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells: vebreltinib, APL-102 and APL-122. Its three immuno-oncology product candidates consist of APL-501, APL-502 and APL-80. Vebreltinib is a potent, oral active selective c-Met inhibitor. APL-102 is an oral active, small molecule Multiple Tyrosine Kinase Inhibitor. APL-122 is a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways. APL-501 is an anti-PD-1 antibody product candidate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tenon Files S-1, Stock Surges 77.57%
- Tenon Stock Offering: Tenon Medical Inc. (TNON) filed a Form S-1 to offer up to 1.81 million shares and 6.98 million warrants at a public offering price of $0.6021 per unit, with potential proceeds aimed at bolstering future growth, especially if a reverse stock split occurs, increasing warrant exercise shares to 8.72 million.
- Azitra's Strategic Shift: Azitra Inc. (AZTR) outlined its 2026 roadmap in a shareholder letter, focusing on the ATR-COSF program for the cosmetic market, with clinical studies expected to start by late 2026, positioning the company for potential commercialization by 2027, enhancing its competitive edge in precision dermatology.
- Nuvectis Licensing Deal: Nuvectis Pharma Inc. (NVCT) announced a strategic licensing agreement with Haisco Pharmaceutical Group for exclusive ex-China rights to two clinical-stage compounds, NXP100 and NXP200, which could open new market opportunities in treating complement-mediated diseases and BRAF mutations.
- REGENXBIO's FDA Alignment: REGENXBIO Inc. (RGNX) has aligned with the FDA for the resubmission of its Biologics License Application for NAVSUNLI, with the FDA acknowledging existing clinical data sufficiency for accelerated approval, anticipating resubmission in Q3 2026, which could significantly impact the company's market position in gene therapy for Hunter syndrome.
See More
Apollomics Reports FY Losses with Declining Revenue
- Loss Report: Apollomics' FY report reveals a GAAP EPS of -$7.57, indicating significant challenges in profitability that could undermine investor confidence and market perception.
- Revenue Decline: The reported revenue of $8.5 million marks a substantial decrease from the previous year, suggesting poor market performance that may complicate future financing efforts.
- Cash Flow Status: As of December 31, 2025, the company's cash, cash equivalents, bank deposits, and money market funds totaled approximately $3.3 million, a sharp decline from $9.8 million in 2024, highlighting increasing liquidity risks.
- Financial Health Warning: The ongoing losses and declining cash flow may force Apollomics to implement austerity measures, impacting its R&D and market expansion plans, thereby exacerbating operational pressures faced by the company.
See More
Apollomics Enters $2 Million Unsecured Convertible Note with CEO
- Financing Arrangement: Apollomics has entered into a $2 million unsecured convertible promissory note with Chairman and CEO Hung-Wen (Howard) Chen, aimed at providing working capital for clinical development programs and general operations, indicating an urgent need for liquidity within the company.
- Interest Rate and Conversion Terms: The note carries a 0% interest rate and will automatically convert into equity upon a future financing of at least $10 million, at a 20% discount to the lowest share price in that round, reflecting a flexible approach in the company's financing strategy to attract investors.
- Board Approval: The transaction has been approved by the company's audit committee and board, with Chen abstaining from the vote, highlighting the transparency of the company's governance structure in significant financial decisions.
- Market Reaction: Following the announcement, Apollomics' stock price fell 5.36% in pre-market trading to $15.0, indicating a cautious market sentiment regarding the company's financing method, which may impact future investor confidence.
See More
Apollomics Signs $2M Convertible Note with CEO for Clinical Development
- Financing Arrangement: Apollomics has entered into a $2 million unsecured convertible promissory note with Chairman and CEO Hung-Wen Chen to provide short-term working capital for advancing clinical development programs and supporting general corporate operations.
- Interest Rate and Conversion Terms: Executed on March 30, 2026, the note carries a 0% interest rate and will automatically convert into Apollomics equity upon closing a future financing round of at least $10 million, with the conversion price set at a 20% discount to the lowest per-share price in the qualifying financing.
- Board Approval: The related-party transaction has been approved by the company's independent Audit Committee and Board, with Chen abstaining from the vote, reflecting the company's commitment to transparency and compliance in its financing decisions.
- Clinical Progress: Apollomics is advancing its lead program, Vebreltinib (APL-101), a selective c-Met inhibitor currently in a Phase 2 multicohort trial for non-small cell lung cancer and other advanced tumors with c-Met alterations across the U.S. and more than 10 additional countries.
See More
Apollomics Narrows H1 Loss to $12.56M Amid Revenue Growth
- Loss Narrowing: Apollomics reported a narrowed loss of $12.56 million for the first half, down from $35.21 million year-over-year, indicating improved financial management and boosting investor confidence.
- R&D Expense Reduction: Research and development expenses decreased significantly from $16.93 million to $4.62 million, reflecting effective cost control measures that could enhance future profitability.
- Revenue Growth: The company generated $8.5 million in revenue for the first half, compared to no revenue in the same period last year, demonstrating positive progress in market outreach and product development, potentially laying the groundwork for sustained growth.
- Strong Cash Position: Apollomics holds $2.1 million in cash and equivalents, which is expected to fund operations into Q3 2026, thereby strengthening its capacity for ongoing clinical trials and research investments.
See More
Apollomics Reports 64% Reduction in Net Loss to $12.5 Million for H1 2025
- Financial Position Improvement: As of June 30, 2025, Apollomics reported cash and cash equivalents of $2.1 million, a significant decrease from $9.8 million as of December 31, 2024, indicating pressure on the company's liquidity management.
- Significant Reduction in R&D Expenses: R&D expenses for the first half of 2025 were $4.6 million, a 73% decrease from $16.9 million in the same period of 2024, reflecting a more cautious approach to research investments by the company.
- Increase in Administrative Expenses: General and administrative expenses rose to $14.5 million in the first half of 2025, up 42% from $10.2 million in the first half of 2024, highlighting cost pressures in operational management.
- Substantial Decrease in Loss Per Share: The net loss per share for the first half of 2025 was $11.37, down 70% from $37.53 in the same period of 2024, demonstrating significant progress in the company's efforts to control losses.
See More
Tenon Files S-1, Stock Surges 77.57%
- Tenon Stock Offering: Tenon Medical Inc. (TNON) filed a Form S-1 to offer up to 1.81 million shares and 6.98 million warrants at a public offering price of $0.6021 per unit, with potential proceeds aimed at bolstering future growth, especially if a reverse stock split occurs, increasing warrant exercise shares to 8.72 million.
- Azitra's Strategic Shift: Azitra Inc. (AZTR) outlined its 2026 roadmap in a shareholder letter, focusing on the ATR-COSF program for the cosmetic market, with clinical studies expected to start by late 2026, positioning the company for potential commercialization by 2027, enhancing its competitive edge in precision dermatology.
- Nuvectis Licensing Deal: Nuvectis Pharma Inc. (NVCT) announced a strategic licensing agreement with Haisco Pharmaceutical Group for exclusive ex-China rights to two clinical-stage compounds, NXP100 and NXP200, which could open new market opportunities in treating complement-mediated diseases and BRAF mutations.
- REGENXBIO's FDA Alignment: REGENXBIO Inc. (RGNX) has aligned with the FDA for the resubmission of its Biologics License Application for NAVSUNLI, with the FDA acknowledging existing clinical data sufficiency for accelerated approval, anticipating resubmission in Q3 2026, which could significantly impact the company's market position in gene therapy for Hunter syndrome.
See More
Apollomics Reports FY Losses with Declining Revenue
- Loss Report: Apollomics' FY report reveals a GAAP EPS of -$7.57, indicating significant challenges in profitability that could undermine investor confidence and market perception.
- Revenue Decline: The reported revenue of $8.5 million marks a substantial decrease from the previous year, suggesting poor market performance that may complicate future financing efforts.
- Cash Flow Status: As of December 31, 2025, the company's cash, cash equivalents, bank deposits, and money market funds totaled approximately $3.3 million, a sharp decline from $9.8 million in 2024, highlighting increasing liquidity risks.
- Financial Health Warning: The ongoing losses and declining cash flow may force Apollomics to implement austerity measures, impacting its R&D and market expansion plans, thereby exacerbating operational pressures faced by the company.
See More
Apollomics Enters $2 Million Unsecured Convertible Note with CEO
- Financing Arrangement: Apollomics has entered into a $2 million unsecured convertible promissory note with Chairman and CEO Hung-Wen (Howard) Chen, aimed at providing working capital for clinical development programs and general operations, indicating an urgent need for liquidity within the company.
- Interest Rate and Conversion Terms: The note carries a 0% interest rate and will automatically convert into equity upon a future financing of at least $10 million, at a 20% discount to the lowest share price in that round, reflecting a flexible approach in the company's financing strategy to attract investors.
- Board Approval: The transaction has been approved by the company's audit committee and board, with Chen abstaining from the vote, highlighting the transparency of the company's governance structure in significant financial decisions.
- Market Reaction: Following the announcement, Apollomics' stock price fell 5.36% in pre-market trading to $15.0, indicating a cautious market sentiment regarding the company's financing method, which may impact future investor confidence.
See More
Apollomics Signs $2M Convertible Note with CEO for Clinical Development
- Financing Arrangement: Apollomics has entered into a $2 million unsecured convertible promissory note with Chairman and CEO Hung-Wen Chen to provide short-term working capital for advancing clinical development programs and supporting general corporate operations.
- Interest Rate and Conversion Terms: Executed on March 30, 2026, the note carries a 0% interest rate and will automatically convert into Apollomics equity upon closing a future financing round of at least $10 million, with the conversion price set at a 20% discount to the lowest per-share price in the qualifying financing.
- Board Approval: The related-party transaction has been approved by the company's independent Audit Committee and Board, with Chen abstaining from the vote, reflecting the company's commitment to transparency and compliance in its financing decisions.
- Clinical Progress: Apollomics is advancing its lead program, Vebreltinib (APL-101), a selective c-Met inhibitor currently in a Phase 2 multicohort trial for non-small cell lung cancer and other advanced tumors with c-Met alterations across the U.S. and more than 10 additional countries.
See More
Apollomics Narrows H1 Loss to $12.56M Amid Revenue Growth
- Loss Narrowing: Apollomics reported a narrowed loss of $12.56 million for the first half, down from $35.21 million year-over-year, indicating improved financial management and boosting investor confidence.
- R&D Expense Reduction: Research and development expenses decreased significantly from $16.93 million to $4.62 million, reflecting effective cost control measures that could enhance future profitability.
- Revenue Growth: The company generated $8.5 million in revenue for the first half, compared to no revenue in the same period last year, demonstrating positive progress in market outreach and product development, potentially laying the groundwork for sustained growth.
- Strong Cash Position: Apollomics holds $2.1 million in cash and equivalents, which is expected to fund operations into Q3 2026, thereby strengthening its capacity for ongoing clinical trials and research investments.
See More
Apollomics Reports 64% Reduction in Net Loss to $12.5 Million for H1 2025
- Financial Position Improvement: As of June 30, 2025, Apollomics reported cash and cash equivalents of $2.1 million, a significant decrease from $9.8 million as of December 31, 2024, indicating pressure on the company's liquidity management.
- Significant Reduction in R&D Expenses: R&D expenses for the first half of 2025 were $4.6 million, a 73% decrease from $16.9 million in the same period of 2024, reflecting a more cautious approach to research investments by the company.
- Increase in Administrative Expenses: General and administrative expenses rose to $14.5 million in the first half of 2025, up 42% from $10.2 million in the first half of 2024, highlighting cost pressures in operational management.
- Substantial Decrease in Loss Per Share: The net loss per share for the first half of 2025 was $11.37, down 70% from $37.53 in the same period of 2024, demonstrating significant progress in the company's efforts to control losses.
See More
